Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 8/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.37 |
| ▸ | TP53 | P04637 | 3/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL1020874 | 1.00 | TSHR (0.38) | TSHRALDH1A1TP53HIF1ACYP3A4 | |
| Hydrochloric Acid SCHEMBL18091194 | 0.97 | TSHR (0.37) | TSHRALDH1A1TP53HIF1ACYP3A4 | |
| SCHEMBL28051179 | 0.97 | TSHR (0.39) | TSHRALDH1A1TP53HIF1ACYP3A4 | |
| SCHEMBL30658 | 0.97 | — | — | |
| SCHEMBL29167478 | 0.95 | TSHR (0.38) | TSHRALDH1A1TP53HIF1ACYP3A4 | |
| SCHEMBL28881367 | 0.95 | TSHR (0.38) | TSHRALDH1A1TP53HIF1ACYP3A4 | |
| Chloromethane SCHEMBL28170022 | 0.95 | TSHR (0.38) | TSHRALDH1A1TP53HIF1ACYP3A4 | |
| SCHEMBL31210190 | 0.95 | TSHR (0.38) | TSHRALDH1A1TP53HIF1ACYP3A4 | |
| Phosphine SCHEMBL28845129 | 0.95 | TSHR (0.38) | TSHRALDH1A1TP53HIF1ACYP3A4 | |
| Methyl Alcohol SCHEMBL28125156 | 0.95 | TSHR (0.38) | TSHRALDH1A1TP53HIF1ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12527788-B2 | Defining RNA-small molecule affinity landscapes enables design of a small molecule inhibitor of an oncogenic non-coding RNA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-01-20 | — | — | US | disclosed |
| US-20240293398-A1 | Defining RNA-Small Molecule Affinity Landscapes Enables Design of a Small Molecule Inhibitor... | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2024-09-05 | — | — | US | disclosed |
| US-11872313-B2 | Prodrug compositions, prodrug nanoparticles, and methods of use thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-01-16 | — | — | US | disclosed |
| EP-4192824-A1 | THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USAGE | Cornell University (US) | 2023-06-14 | — | — | EP | disclosed |
| WO-2022031772-A1 | THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USAGE | CORNELL UNIVERSITY (US) | 2022-02-10 | — | — | WO | disclosed |
| US-11141379-B2 | Prodrug compositions, prodrug nanoparticles, and methods of use thereof | WASHINGTON UNIVERSITY (US) | 2021-10-12 | — | — | US | disclosed |
| US-11092594-B2 | Haptens, hapten conjugates, compositions thereof and method for their preparation and use | VENTANA MEDICAL SYSTEMS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-20210206809-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY | VERA THERAPEUTICS INC (US) | 2021-07-08 | — | — | US | disclosed |
| US-20210171437-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO | VERA THERAPEUTICS INC (US) | 2021-06-10 | — | — | US | disclosed |
| US-20210115491-A1 | Assay for High-Throughput Identification of Therapeutic Compounds | Middle Tennessee State University (US) | 2021-04-22 | — | — | US | disclosed |
| WO-2004037772-A1 | CONVENIENT AND SCALABLE SYNTHESIS OF ETHYL N-[(2-BOC-AMINO) ETHYL] GLYCINATE AND ITS HYDROCHLORIDE SALT | THE UNIVERSITY OF WESTERN ONTARIO (CA) | 2004-05-06 | — | — | WO | disclosed |
| US-6624157-B2 | Antitumor agents | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-23 | — | — | US | disclosed |
| WO-2003047515-A2 | P2X7 RECEPTOR ANTAGONISTS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2003-06-12 | — | — | WO | disclosed |
| EP-1200432-A4 | AMIDO SPIROPIPERIDINES PROMOTE THE RELEASE OF GROWTH HORMONE | MERCK & CO INC (US) | 2003-01-29 | — | — | EP | disclosed |
| EP-1200432-A1 | AMIDO SPIROPIPERIDINES PROMOTE THE RELEASE OF GROWTH HORMONE | Merck & Co., Inc. (US) | 2002-05-02 | — | — | EP | disclosed |
| US-20010039273-A1 | Thiadioxobenzodiazepine inhibitors of farnesyl protein transferase | DING CHARLES Z (US) | 2001-11-08 | — | — | US | disclosed |
| EP-0918771-A4 | THIADIOXOBENZODIAZEPINE INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL MYERS SQUIBB CO (US) | 2001-02-07 | — | — | EP | disclosed |
| WO-2001004119-A1 | AMIDO SPIROPIPERIDINES PROMOTE THE RELEASE OF GROWTH HORMONE | MERCK & CO., INC. (US) | 2001-01-18 | — | — | WO | disclosed |
| EP-0918771-A1 | THIADIOXOBENZODIAZEPINE INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-06-02 | — | — | EP | disclosed |
| WO-1998002436-A1 | THIADIOXOBENZODIAZEPINE INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115491-A1 | Assay for High-Throughput Identification of Therapeutic Compounds | BACE1, FURIN, BACE2 | TSHR 3848/4885ALDH1A1 1720/4885TP53 2986/4885 |
| US-12527788-B2 | Defining RNA-small molecule affinity landscapes enables design of a small molecule inhibitor of an oncogenic non-coding RNA | STUB1, TARBP1, STK16 | TSHR 1439/4885ALDH1A1 3749/4885TP53 36/4885 |
| US-20210171437-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO | TARBP1, TIA1, SSB | TSHR 158/4885ALDH1A1 4569/4885TP53 911/4885 |
| US-11141379-B2 | Prodrug compositions, prodrug nanoparticles, and methods of use thereof | FAP, PNP, TYMP | TSHR 3981/4885ALDH1A1 404/4885TP53 291/4885 |
| US-20240293398-A1 | Defining RNA-Small Molecule Affinity Landscapes Enables Design of a Small Molecule Inhibitor... | TARBP1, STK16, STK38 | TSHR 1639/4885ALDH1A1 3443/4885TP53 50/4885 |
| US-20210206809-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY | AGO2, TARBP1, TPR | TSHR 105/4885ALDH1A1 4394/4885TP53 1720/4885 |
| US-11872313-B2 | Prodrug compositions, prodrug nanoparticles, and methods of use thereof | FAP, PNP, TYMP | TSHR 3981/4885ALDH1A1 404/4885TP53 291/4885 |
| US-20010039273-A1 | Thiadioxobenzodiazepine inhibitors of farnesyl protein transferase | CBR1, CBR3, FNTB | TSHR 201/4885ALDH1A1 3049/4885TP53 1154/4885 |
| US-11092594-B2 | Haptens, hapten conjugates, compositions thereof and method for their preparation and use | CRBN, AHR, RORB | TSHR 544/4885ALDH1A1 2734/4885TP53 3581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.